Intuitive Surgical (NASDAQ:ISRG) Stock Price Down 1.4% – Here’s What Happened

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) dropped 1.4% during trading on Monday . The stock traded as low as $563.35 and last traded at $576.08. Approximately 710,376 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 1,914,490 shares. The stock had previously closed at $584.05.

Wall Street Analyst Weigh In

ISRG has been the subject of a number of recent analyst reports. Barclays upped their price target on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday. Jefferies Financial Group upped their target price on Intuitive Surgical from $475.00 to $575.00 in a research note on Monday. JPMorgan Chase & Co. lifted their price target on Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. CICC Research initiated coverage on Intuitive Surgical in a research note on Monday. They issued a “neutral” rating and a $550.00 price objective on the stock. Finally, UBS Group boosted their target price on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Price Performance

The stock has a 50-day moving average price of $548.70 and a 200-day moving average price of $507.04. The company has a market capitalization of $203.99 billion, a P/E ratio of 92.08, a P/E/G ratio of 5.19 and a beta of 1.39.

Insider Transactions at Intuitive Surgical

In related news, insider Jamie Samath sold 22,903 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the transaction, the insider now owns 8,757 shares in the company, valued at $4,597,425. The trade was a 72.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,967,734. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,749 shares of company stock worth $15,303,875. Company insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ISRG. Berbice Capital Management LLC bought a new stake in Intuitive Surgical during the 4th quarter valued at $26,000. Godsey & Gibb Inc. raised its holdings in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 35 shares during the last quarter. MidAtlantic Capital Management Inc. bought a new position in Intuitive Surgical in the 3rd quarter valued at about $33,000. Decker Retirement Planning Inc. bought a new stake in Intuitive Surgical during the 4th quarter worth approximately $36,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Intuitive Surgical in the third quarter worth approximately $38,000. Institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.